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Background: HIV-associated TB is a serious public health problem in Myanmar. Study objectives were to
describe national scale-up of collaborative activities to reduce the double burden of TB and HIV from 2005 to
2016 and to describe TB treatment outcomes of individuals registered with HIV-associated TB in 2015 in the
Mandalay Region.
Methods: Secondary analysis of national aggregate data and, for treatment outcomes, a cohort study of
patients with HIV-associated TB in the Mandalay Region.
Results: The number of townships implementing collaborative activities increased from 7 to 330 by 2016. The
number of registered TB patients increased from 1577 to 139 625 in 2016, with the number of individuals
tested for HIV increasing from 432 to 114 180 (82%) in 2016: 10 971 (10%) were diagnosed as HIV positive.
Uptake of co-trimoxazole preventive therapy (CPT) and antiretroviral therapy (ART) nationally in 2016 was
77% and 52%, respectively. In the Mandalay Region, treatment success was 77% and mortality was 18% in
815 HIV-associated TB patients. Risk factors for unfavourable outcomes and death were older age (≥45 years)
and not taking CPT and/or ART.
Conclusion: Myanmar is making good progress with reducing the HIV burden in TB patients, but better imple-
mentation is needed to reach 100% HIV testing and 100% CPT and ART uptake in TB–HIV co-infected patients.
Keywords: Antiretroviral therapy, Co-trimoxazole preventive therapy, HIV, Mandalay, Myanmar, Tuberculosis
Introduction
Despite steady progress in the implementation of the global
Directly Observed Treatment, Short-Course (DOTS) and subse-
quently the Stop TB strategy since 1995, TB remains an enormous
global public health challenge. In 2015, the total number of new
cases globally was estimated at 10.4 million and the number of
deaths due to TB was estimated at 1.8 million.1 In the same year,
about 1.2 million people worldwide (11% of all new TB cases) were
thought to develop HIV-associated TB and there were 400 000
HIV-associated TB deaths (22% of all TB deaths).1 While the
African Region is the one most affected by HIV-associated TB, the
South-East Asian Region and the Western Paciﬁc together account
for 22% of the global HIV-associated TB patients, with India,
Indonesia, Myanmar, Thailand, China and Vietnam comprising the
majority.1
HIV adversely affects TB control efforts. Not only is HIV asso-
ciated with large increases in TB cases, but it also leads to
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increased mortality during and after anti-TB treatment.2 In 2004
the WHO launched an interim policy document on TB–HIV collab-
orative activities3 and followed this in 2012 with an updated policy
that consolidated evidence about the efﬁcacy and effectiveness of
HIV-associated TB interventions from randomized controlled trials,
observational studies, operational research and best practices
from programme implementation.4 To reduce the burden of HIV in
TB patients, the key interventions are HIV testing and ensuring that
HIV-infected TB patients are started on co-trimoxazole preventive
therapy (CPT) and antiretroviral therapy (ART) as soon as possible
after starting anti-TB treatment. In HIV-infected TB patients, CPT is
associated with a 25–46% mortality reduction and ART with a
64–95% mortality reduction, with a synergistic effect being
observed when the two interventions are combined.5
Myanmar is one of the 30 most HIV-associated TB high bur-
den countries in the world,1 and in 2014 a sero-sentinel surveil-
lance study documented an HIV prevalence in TB patients of
8.5%.6 Following the 2004 WHO interim policy, TB–HIV collab-
orative activities in the country started in 2005 in seven town-
ships. The focus of these activities was to reduce the burden of
HIV in TB, and the activities have gradually expanded to the
whole country of 330 townships. It is important for the national
TB and AIDS programmes to obtain a countrywide picture of the
increase in townships adopting activities to reduce the burden
of HIV in TB, including the numbers and proportions of regis-
tered TB patients being tested for HIV and for those who are
HIV positive, the numbers and proportions starting on CPT and
ART. In 2010 there was a report showing good HIV testing rates
and uptake of ART in the integrated HIV care programme for TB
patients in the Mandalay Region and presenting generally good
outcome results.7
With the 2012 updated WHO policy re-emphasizing the need
for CPT and ART in all HIV-associated TB patients, with the latter
started as soon as possible after initiating TB treatment regard-
less of the CD4 cell count, it is also important to know how well
these interventions are currently being implemented in Myanmar
and whether they have any beneﬁcial effect on TB-speciﬁc treat-
ment outcomes. It is also important to know whether there are
other factors associated with poor treatment outcomes, e.g.,
gender, older age (as a result of comorbidities) and types and
categories of TB, that can be addressed with speciﬁc interven-
tions. The objectives of this study therefore were to describe at
the national level the scale-up and implementation of TB–HIV
collaborative activities to reduce the burden of HIV in TB patients
at the township level and in registered TB patients in Myanmar
between 2005 and 2016 and to describe the TB treatment out-
comes of individual patients registered with HIV-associated TB in
the Mandalay Region in 2015.
Materials and methods
Study design
For the national study on scale-up of TB–HIV collaborative activ-
ities, this was a secondary analysis of national aggregate data
on townships and patients registered with TB. For the TB treat-
ment outcome study, this was a cohort study using secondary
data of individual patients registered with HIV-associated TB.
Study setting
General
Myanmar is situated in South-East Asia and has an estimated
population of slightly more than 51 million, 70% of whom live in
rural areas, according to the Myanmar National Census conducted
in 2014.8 There are 135 ethnic groups, most of whom are poor,
with low levels of education. The country is divided administratively
into 15 states/regions, 74 districts and 330 townships.
There is a National TB Program (NTP) that, together with
partners, offers free-of-charge diagnostic, treatment and follow-
up services for patients with presumptive and conﬁrmed TB,
based on the WHO 2010 TB treatment guidelines.9 There is also
a National AIDS Program (NAP) that, together with partners,
offers HIV testing and counselling, and for those found to be
HIV positive, care, CPT and ART according to criteria that are in
operation at that time.10,11 For people living with HIV, TB screen-
ing is also regularly carried out: those identiﬁed with presump-
tive TB are referred to the NTP for further investigation while
those with no TB-related symptoms are considered for isoniazid
preventive therapy provided there are no contraindications.
From 2005, TB and HIV/AIDS control activities were mainly
supported by the government along with a number of bilateral
international donors. In 2011, Myanmar received ﬁnancial sup-
port from the Global Fund Against AIDS, Tuberculosis and
Malaria (GFATM) in two phases (2011–2012 and 2013–2015).
During the second phase, the GFATM launched a new funding
model and provided performance-based funding that included
strong support for the scaling up of TB–HIV collaborative activ-
ities in order to assist the country in trying to achieve 100% HIV
testing uptake and 100% uptake of CPT and ART in co-infected
patients and in meeting or exceeding the global target for HIV-
associated TB treatment success at 75%.4,12
TB–HIV collaborative activities at the township level
Every township has a TB centre that offers sputum smear micros-
copy for patients presenting with presumptive TB. Those found to be
smear-positive are diagnosed as smear-positive pulmonary TB (PTB).
For those found to be smear-negative, a clinical and radiographic
algorithm for diagnosing smear negative pulmonary TB or extra-
pulmonary TB (EPTB) is applied. The Xpert MTB/RIF (Mycobacterium
tuberculosis/resistance to rifampicin) assay is used in those known
to be HIV infected. Patients diagnosed with TB are registered and
started on standardized anti-TB treatment that is in line with the
WHO TB treatment guidelines.9
All registered TB patients are offered HIV testing using rapid
diagnostic tests with Determine (AlereDetermine HIV-1/2, Alere
International, Galway, Ireland), UniGold (Trinity Biotech, Wicklow,
Ireland) and STAT-PAK (Chembio Diagnostic Systems, Medford, NY,
USA). Initially, HIV testing was done by NAP staff, but since 2014,
HIV testing has been undertaken by NTP staff. HIV-positive TB
patients are offered immediate CPT, which was provided ﬁrst
through the NTP staff up to 2014 and since then from the NAP
staff for the duration of TB treatment. From 2005, HIV-infected TB
patients were offered ART through the NAP staff only if their CD4
lymphocyte count was <200 cells/mm3. From 2012, the criteria
for starting ART changed: HIV-infected TB patients were offered
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ART if their CD4 lymphocyte count was <500 cells/mm3. In 2015,
this changed again, with recommendations that all HIV-infected
TB patients start ART regardless of their CD4 count.13 Again, ART is
always offered and managed by NAP staff. The ART regimen from
2005 was a stavudine-based regimen, but in 2015 this changed
to a tenofovir-based regimen.
All TB patients are monitored using paper-based treatment
cards and registers using standardized deﬁnitions for case ﬁnd-
ing and treatment outcomes.9 HIV testing and HIV results are
recorded in the township TB centre laboratory register and TB
treatment register, with the latter also recording whether CPT
and/or ART has been initiated. The data from each township are
sent on a quarterly basis to the regional centres, where they are
collated and sent on to the national programme for further col-
lation into national quarterly reports. These in turn form the
basis of national annual reports.
Townships and study population
For the national study, the units for assessment were townships
implementing TB–HIV collaborative activities and all patients
registered with TB in Myanmar between 2005 and 2016. For the
individual patient study, the population included all patients
registered with HIV-associated TB in the 28 townships in the
Mandalay Region between January and December 2015.
Data variables, sources of data and data collection
For the national study, data variables included year, townships
implementing TB–HIV collaborative activities, number of TB
patients registered each year in the townships and numbers of
patients HIV tested, HIV positive, placed on CPT and started on
ART. Sources of data were the national annual TB reports from
2005 to 2015 and the NTP electronic database for 2016.
For the individual patient study in the Mandalay Region, data
variables included year, TB registration number, name of the town-
ship, gender, age, category of TB (new, relapse, treatment after
loss to follow-up, treatment after failure, other previously treated),
type of TB (pulmonary and extrapulmonary), started on CPT,
started on ART and TB treatment outcomes (cured, completed
treatment, loss to follow-up, died, failed, not evaluated [trans-
ferred out] and moved to second-line treatment). Treatment suc-
cess was deﬁned as cured plus treatment completed and
unfavourable treatment outcomes were deﬁned as everything
else. The source of data was the NTP electronic database ﬁle, the
NAP-ART register and the Union electronic database ﬁle for the
Mandalay Region for 2015.
Analysis and statistics
Aggregate nationwide data for Myanmar were extracted from the
annual TB reports and NTP electronic database into an Excel ﬁle
(Microsoft, Redmond,WA, USA). Similarly, individual patient data for
the Mandalay Region were extracted from the electronic databases
and the NAP-ART register into another Excel ﬁle. For the national
data, frequencies and proportions were described and analysed. For
individual patient data, demographic and clinical characteristics
related to unfavourable treatment outcomes or death were
compared using the χ2 test with results presented as RRs and 95%
CIs. Adjusted RRs (with 95% CIs) were calculated by plotting a mul-
tivariable predictive model (log binomial for unfavourable treatment
outcomes and modiﬁed Poisson for death). Levels of signiﬁcance
were set at 5% (p<0.05).
Ethics
Permission to use the secondary data for this study was obtained
from the NTP and NAP.
Results
National aggregate data
The number of townships in Myanmar implementing TB–HIV col-
laborative activities between 2005 and 2016 is shown in
Figure 1. Initially there were just seven townships, and this
increased gradually to 30 by 2013. In 2014 there was a rapid
expansion and all townships in the country were implementing
TB–HIV collaborative activities by 2016.
The annual number of registered TB patients in these town-
ships, along with those knowing their HIV status and HIV posi-
tivity between 2005 and 2016, are shown in Figure 2. Initially
there were just 1577 registered patients, with the number grad-
ually increasing to 13 718 in 2012. Thereafter there was rapid
expansion, with the registered number of TB patients increasing
to 139 625 in 2016. The proportion of patients with known HIV
status (newly tested or HIV result already known) varied from
year to year, but in the years 2013–2016 it increased progres-
sively (2013, 44%; 2014, 60%; 2015, 76%; 2016, 82%). HIV
positivity also varied from year to year, but in the 3 years from
2014 to 2016, the proportion diagnosed as HIV positive was
fairly stable at between 9 and 11%.
Annual uptake of CPT and ART among TB–HIV co-infected
patients is shown in Figures 3 and 4. For CPT, there were no data
pertaining just to the townships for 2008–2010. There was vari-
able uptake in the early years when the number of patients was
low, but from 2013 to 2016 uptake was between 72 and 89%.
For ART, annual uptake was between 60 and 98% for
2008–2011. From 2013 onwards, the total numbers accessing
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Figure 1. Townships implementing TB–HIV collaborative activities in
Myanmar, 2005–2016.
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ART increased but the proportion of patients on ART varied,
though it had increased to 52% in 2016.
Regional individual data
The characteristics of 815 TB–HIV co-infected patients regis-
tered in the Mandalay Region in 2015 are shown in Table 1.
Most were 15–44 years of age, two-thirds were male and the
majority had new pulmonary TB. Nearly three-quarters of the
patients were on CPT and ART. Treatment outcomes for the
entire cohort are shown in Table 2. Treatment success was 77%,
with the main cause of an unfavourable treatment outcome in
the remaining 23% being death. Characteristics associated with
an unfavourable treatment outcome or with death are shown in
Tables 3 and 4. The main factors signiﬁcantly associated with an
increased risk of unfavourable treatment outcome and/or death
were age ≥45 years, taking CPT alone (signiﬁcant only for
death), taking no adjunctive therapy at all or having no details
recorded of adjunctive therapy (signiﬁcant only for death) com-
pared with the reference values.
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Figure 2. Annual registered patients with TB with known HIV status and
HIV positivity in townships implementing TB–HIV collaborative activities in
Myanmar, 2005–2016.
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Table 1. Demographic and clinical characteristics of patients
registered with HIV-associated TB in the Mandalay Region,
Myanmar, 2015
Characteristics n (%)
Total 815 (100)
Age group in years
≤14 63 (8)
15–44 606 (74)
≥45 146 (18)
Gender
Male 564 (69)
Female 251 (31)
Category of TB
New 718 (88)
Relapse 86 (11)
Treatment after LTFU 4 (<1)
Treatment after failure 7 (1)
Type of TB
Pulmonary 656 (81)
Extrapulmonary 159 (19)
Adjunctive therapy
CPT alone 162 (20)
ART alone 34 (4)
CPT and ART together 598 (73)
No adjunctive treatment 14 (2)
No information 7 (1)
ART=antiretroviral therapy; CPT=co-trimoxazole preventive therapy;
LTFU=loss to follow-up.
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Discussion
This is the ﬁrst study in Myanmar to describe the scale-up of
TB–HIV collaborative activities at the national level between
2005 and 2016 and to assess at the individual level how HIV
care and treatment for HIV-associated TB patients related to TB
treatment outcomes. There were some interesting ﬁndings.
First, from 2005 to 2013 there was a gradual scale-up of town-
ships implementing collaborative activities focused on HIV testing
and providing care and treatment for HIV-associated TB patients.
Since 2013, however, there has been a dramatic expansion and all
townships implemented collaborative activities by 2016. This
increase in TB–HIV collaborative activities, along with the shifting in
responsibilities for HIV testing and initiation of CPT and ART, coin-
cided with the implementation of GFATM performance-based
ﬁnancing,12 which emphasizes the crucial importance of targeted
international support if large-scale change in countries is desired.
Since 2002, the GFATM has provided more than three-quarters of
all international ﬁnancing for global TB control, disbursing US$4.7
billion in more than 100 countries.14 In 2013 the GFATM launched
its new funding model, which seeks to enhance a synergistic
response to HIV-associated TB epidemics and build the necessary
resilient and sustainable health systems that underpin TB–HIV col-
laborative activities.14 Myanmar is an example of what can be
done if adequate resources are made available and there is the
political will to move forward.
Second, with GFATM support there has been a remarkable
increase in the numbers and proportions of TB patients in Myanmar
tested for HIV, which in 2016 reached 82%. HIV testing (with the
important logistics of ensuring uninterrupted supplies of test kits)
Table 2. Treatment outcomes of patients registered with HIV-
associated TB in the Mandalay Region, Myanmar, 2015
Treatment outcomes n (%)
Total enrolled for treatment 815 (100)
Treatment success 624 (77)
Cured 295 (36)
Treatment completed 329 (41)
Unfavourable treatment outcomes 191 (23)
Loss to follow-up 18 (2)
Died 146 (18)
Failed 9 (1)
Not evaluated (transferred out) 11 (1)
Changed to second-line treatment 7 (1)
Table 3. Demographic and clinical characteristics of patients registered with HIV-associated TB in the Mandalay Region, Myanmar, 2015, in
relation to unfavourable treatment outcomes
Characteristics Enrolled for treatment, n Unfavourable outcomes, n (%) RR (95% CI) aRR (95% CI) p-Value
Total 815 191 (23) — — —
Age group in years
≤14 63 10 (16) 0.7 (0.4 to 1.3) 0.8 (0.4 to 1.4) 0.4
15–44 606 131 (22) Ref 1 Ref
≥45 146 50 (34) 1.6 (1.2 to 2.1) 1.6 (1.2 to 2.1) <0.001
Gender
Male 564 123 (22) Ref 1 Ref
Female 251 68 (27) 1.2 (0.9 to 1.6) 1 (0.7 to 1.3) 0.8
Category of TB
New 718 166 (23) Ref 1 Ref
Relapse 86 25 (29) 1.3 (0.9 to 1.8) 0.8 (0.5 to 1.2) 0.3
Treatment after LTFU 4 0 (0) — — —
Treatment after failure 7 0 (0) — — —
Type of TB
Pulmonary 656 148 (23) Ref 1 Ref
Extrapulmonary 159 43 (27) 1.2 (0.9 to 1.6) 1.0 (0.7 to 1.4) 0.9
Adjunctive therapy
CPT alone 162 81 (50) 3.3 (2.5 to 4.1) 1.2 (0.9 to 1.6) 0.2
ART alone 34 4 (12) 0.8 (0.3 to 2.0) 1.6 (1.0 to 2.6) 0.1
CPT and ART together 598 92 (15) Ref 1 Ref
No adjunctive treatment 14 9 (64) 4.2 (2.7 to 6.4) 1.9 (1.0 to 3.6) 0.04
No information 7 5 (71) 4.6 (2.8 to 7.7) 2.1 (1.0 to 4.7) 0.1
p-Values are presented for aRR.
aRR=adjusted relative risk; ART=antiretroviral therapy; CPT=co-trimoxazole preventive therapy; LTFU=loss to follow-up; Ref=reference.
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has been able to keep pace with the large numbers of HIV-
associated TB patients enrolled in care. In 2015, globally about 55%
of TB patients had a documented HIV result, with the level of HIV
testing in the 30 high HIV-associated TB burden countries averaging
64%,1 so Myanmar is performing well in this regard.With more than
three-quarters of TB patients taking up provider-initiated HIV testing
and counselling in the last 3 years, the prevalence of HIV appears to
have stabilized at about 10%. This probably presents a true picture
of the prevalence of HIV among TB patients in the country, as in pre-
vious years, with fewer patients being tested, it is possible that test-
ing was only offered to those suspected of having HIV, biasing the
observed prevalence upwards.
Third, while the uptake of CPT in HIV-associated TB patients
has been reasonable at between 70 and 90% in the last 4 years,
the same cannot be said for ART, where uptake has been on
average below or just above 50%. In 2015, globally about 78%
of notiﬁed HIV-associated TB patients were reported to be on
ART, with the proportion being 80% in high HIV-associated TB
burden countries.1 It is possible that in Myanmar there is a
weakness of recording and reporting of CPT and ART uptake at
the township level, as our regional study in Mandalay, which
focused on individual patients, found CPT and ART uptakes to be
greater than 90% and 75%, respectively.
Fourth, in the Mandalay study, HIV-associated TB patients had
generally good treatment success, exceeding the global target of
75%. The overall unfavourable treatment outcome was 23%, which
was predominately due to a high mortality approaching 20%. The
low loss to follow-up of 2% bears testimony to good tracking of
patients during treatment. The main factors associated with both
an unfavourable treatment outcome and death were older age
(≥45 years) and being on CPTalone or on neither CPTor ART.
The ﬁndings in Mandalay on age concur with previous studies
documenting worse treatment outcomes in older adults.15,16
There are various possible explanations.When diagnostic resources
are limited, it is possible that older patients have a higher preva-
lence of chronic lung disease with various aetiologies that are
potentially misdiagnosed as PTB and without speciﬁc treatment
mortality may be higher with these chronic respiratory conditions.
Older patients may also have other comorbidities that compromise
TB treatment outcomes. Diabetes mellitus is known to adversely
affect TB treatment outcomes by increasing the risk of death or
treatment failure in patients with dual disease,17 and particularly
so if patients have both diabetes and are current smokers.18 Large
studies conducted in China and India, using fasting blood glucose
as the diagnostic method, found the diabetes prevalence in TB
patients to be between 12 and 13%, with a signiﬁcant proportion
having diabetes newly diagnosed as a result of active screening
initiatives.19,20
While CPT reduces mortality risk in people living with HIV and
results in fewer episodes of malaria and increased overall life
Table 4. Demographic and clinical characteristics of patients registered with HIV-associated TB in the Mandalay Region, Myanmar, 2015, in
relation to death
Characteristics Enrolled for treatment, n Death, n (%) RR (95% CI) aRR (95% CI) p-Value
Total 815 146 (18)
Age group in years
≤14 63 9 (14) 0.9 (0.5 to 1.7) 0.8 (0.4 to 1.5) 0.5
15–44 606 97 (16) Ref 1 Ref
≥45 146 40 (27) 1.7 (1.2 to 2.4) 1.6 (1.2 to 2.2) <0.01
Gender
Male 564 96 (27) Ref Ref
Female 251 50 (20) 1.2 (0.9 to 1.6) 1.2 (0.9 to 1.6) 0.3
Category of TB
New 718 129 (18) Ref 1 Ref
Relapse 86 17 (20) 1.1 (0.7 to 1.7) 1.2 (0.8 to 1.9) 0.4
Treatment after LTFU 4 0 (0) — — —
Treatment after failure 7 0 (0) — — —
Type of TB
Pulmonary 656 111 (17) Ref 1 Ref
Extrapulmonary 159 35 (22) 1.3 (0.9 to 1.8) 1.4 (1.0 to 1.9) 0.04
Adjunctive therapy
CPT alone 162 67 (41) 3.9 (2.9 to 5.2) 3.7 (2.7 to 4.9) <0.001
ART alone 34 3 (9) 0.8 (0.3 to 2.5) 0.9 (0.3 to 2.6) 0.8
CPT and ART together 598 64 (11) Ref 1 Ref
No adjunctive treatment 14 9 (64) 6.0 (3.8 to 9.5) 6.5 (4.2 to 9.9) <0.001
No information 7 3 (43) 4.0 (1.6 to 9.7) 4.2 (1.6 to 10.8) <0.01
p-Values are presented for aRR.
ART=antiretroviral therapy; aRR=adjusted relative risk; CPT=co-trimoxazole preventive therapy; LTFU=loss to follow-up; Ref=reference.
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expectancy,21 its effects are limited when used on its own, as
shown in our current study. The key intervention is ART, preferably
used in conjunction with CPT, and this has been shown in clinical
trials to greatly reduce mortality, especially if used early in the
course of anti-TB treatment.22,23 This is in agreement with
another recent study in Myanmar that found excellent treatment
outcomes among HIV-associated TB patients started on ART.24
The strengths of this study were the national sample assessed
over a 12-year period and the large number of patients enrolled in
the Mandalay Region in 2015. We also adhered to Strengthening
the Reporting of Observational Studies in Epidemiology guidelines
for the conduct and reporting of this observational study.25
Limitations relate to the retrospective operational nature of the
study, which relied on a mix of paper-based and electronic
national aggregate reports for the national data and three differ-
ent sources for the individual data. For the national reports, we
were unable to obtain speciﬁc township CPT data for 3 years from
2008 to 2010, and we do not know whether the low ART uptake
was due to incomplete recording and reporting or failure of imple-
mentation. For the individual data, we also did not collect infor-
mation about when CPT or ART was started (either before or after
the start of anti-TB treatment) or about drug resistance, yet both
of these may be determinants of treatment outcome.
There are some programmatic implications from this study.
First, with collaborative activities to reduce the double burden of
TB and HIV now expanded to all townships in the country, it will
be important to improve on quality and obtain maximum bene-
ﬁt by ensuring as close to 100% HIV testing of registered TB
patients as possible, and for those who are HIV positive, 100%
uptake of CPT and ART. This will require sustained funding, good
working relationships between the NAP and NTP at all levels,
uninterrupted supplies of consumables and drugs, prompt initi-
ation of ART after starting anti-TB treatment and accurate, com-
prehensive recording and reporting of HIV parameters in TB
treatment cards and registers.
Second, the growing burden of non-communicable diseases
in patients with HIV and TB needs to be recognized and
addressed if mortality is to be reduced.26 Screening TB patients
for diabetes, which has already started in a phased approach in
Myanmar, should be evaluated and, if deemed feasible and cost
effective, scaled up as recommended by the WHO and the
International Union Against Tuberculosis and Lung Disease.27
Decisions will need to be made about whether to screen all
patients or those most at risk based on, for example, age, body
mass index or smoking status.
Finally, Myanmar needs to fully embrace the other important
TB–HIV collaborative activity of reducing the double burden of TB
and HIV by getting all people infected with HIV on ART, as recom-
mended in the recent guidance by the WHO,28 and considering
the additional use of isoniazid preventive therapy, which further
reduces the risk of TB.29 There is growing evidence that at the
population level, the scale-up of ART with high levels of coverage
is associated with a signiﬁcant decline in the national burden of
TB, both for HIV-infected and non-infected communities.30
In conclusion, in the 12 years from 2005 to 2016, Myanmar has
expanded TB–HIV collaborative activities to its townships to reduce
the double burden of TB and HIV, and there has been a signiﬁcant
increase in registered TB patient numbers, HIV testing uptake and
initiation of CPT and ART in HIV-associated TB patients since 2013.
Although at the national level ART uptake in HIV-associated TB
patients is about 50%, this is higher (at >75%) in the Mandalay
Region and is associated with good treatment outcomes. Risk fac-
tors for unfavourable outcomes and death include age ≥45 years
and no adjunctive treatment with CPT and/or ART. These ﬁndings
have programmatic implications for moving forward.
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